Neutrophilic and Pustular Eruptions

  • Sigrid M. C. MöckelEmail author
  • Dieter Metze


This chapter reviews noninfectious inflammatory dermatoses with mainly neutrophilic infiltrates and the formation of pustules. The infiltrate containing neutrophils may be either mild as in urticaria or very dense, even with leukocytoclasia as in Sweet syndrome or pyoderma gangrenosum. Neutrophilic infiltrates and pustular eruptions are caused by different noninfectious immunomechanisms. For some of them, mutations have been found (e.g., NLRC4 mutation in cryopyrin-associated periodic syndromes (CAPS) leading to activation of the inflammasome; IL36RN mutation in pustular psoriasis resulting in uncontrolled IL36-signaling). Neutrophilic dermatoses are of high interest, as they may present dermatological reaction patterns of underlying benign or malignant conditions.


Neutrophilic dermatoses Pustular Neutrophilic urticarial dermatosis Sweet syndrome Autoinflammatory Aseptic 


  1. 1.
    Kasha EE Jr, Epinette WW. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) in association with a monoclonal IgA gammopathy: a report and review of the literature. J Am Acad Dermatol. 1988;19(5 Pt 1):854–8.CrossRefGoogle Scholar
  2. 2.
    Kretschmer L, Maul J-T, Hofer T, Navarini AA. Interruption of Sneddon-Wilkinson subcorneal pustulation with infliximab. Case Rep Dermatol. 2017;9(1):140–4.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Patel R, Cafardi JM, Patel N, et al. Tumor necrosis factor biologics beyond psoriasis in dermatology. Expert Opin Biol Ther. 2011;11(10):1341–59.CrossRefGoogle Scholar
  4. 4.
    Grob JJ, Mege JL, Capo C, et al. Role of tumor necrosis factor-alpha in Sneddon-Wilkinson subcorneal pustular dermatosis. A model of neutrophil priming in vivo. J Am Acad Dermatol. 1991;25(5 Pt 2):944–7.CrossRefGoogle Scholar
  5. 5.
    Pinkus H. Is subcorneal pustular dermatosis of Sneddon and Wilkinson and entity sui generis? Am J Dermatopathol. 1981;3(4):379–80.CrossRefGoogle Scholar
  6. 6.
    Letter LBL. Subcorneal pustular dermatosis vs pustular psoriasis. Arch Dermatol. 1974;110(1):131.Google Scholar
  7. 7.
    Navarini AA, Satoh TK, French LE. Neutrophilic dermatoses and autoinflammatory diseases with skin involvement-innate immune disorders. Semin Immunopathol. 2016;38(1):45–56.CrossRefGoogle Scholar
  8. 8.
    Sneddon IB, Wilkinson DS. Subcorneal pustular dermatosis. Br J Dermatol. 1956;68(12):385–94.CrossRefGoogle Scholar
  9. 9.
    Reed J, Wilkinson J. Subcorneal pustular dermatosis. Clin Dermatol. 2000;18(3):301–13.CrossRefGoogle Scholar
  10. 10.
    Patton D, Lynch PJ, Fung MA, Fazel N. Chronic atrophic erosive dermatosis of the scalp and extremities: a recharacterization of erosive pustular dermatosis. J Am Acad Dermatol. 2007;57(3):421–7.CrossRefGoogle Scholar
  11. 11.
    Feramisco JD, Goerge T, Schulz SE, et al. Disseminated erosive pustular dermatosis also involving the mucosa: successful treatment with oral dapsone. Acta Derm Venereol. 2012;92(1):91–2.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wilk M, Zelger BG, Hauser U, et al. Erosive pustular dermatosis of the scalp: reappraisal of an underrecognized entity. J Dtsch Dermatol Ges. 2018;16(1):15–9.PubMedGoogle Scholar
  13. 13.
    Marchini G, Ståbi B, Kankes K, et al. AQP1 and AQP3, psoriasin, and nitric oxide synthases 1–3 are inflammatory mediators in erythema toxicum neonatorum. Pediatr Dermatol. 2003;20(5):377–84.CrossRefGoogle Scholar
  14. 14.
    Marchini G, Ulfgren A-K, Loré K, et al. Erythema toxicum neonatorum: an immunohistochemical analysis. Pediatr Dermatol. 2001;18(3):177–87.CrossRefGoogle Scholar
  15. 15.
    Reginatto FP, Muller FM, Peruzzo J, Cestari TF. Epidemiology and predisposing factors for erythema toxicum neonatorum and transient neonatal pustular: a multicenter study. Pediatr Dermatol. 2017;34(4):422–6.CrossRefGoogle Scholar
  16. 16.
    Van Praag MCG, Van Rooij RWG, Folkers E, et al. Diagnosis and treatment of pustular disorders in the neonate. Pediatr Dermatol. 1997;14(2):131–45.CrossRefGoogle Scholar
  17. 17.
    Freeman RG, Spiller R, Knox JM. Histopathology of erythema toxicum neonatorum. Arch Dermatol. 1960;82:586–9.CrossRefGoogle Scholar
  18. 18.
    Lucky AW, Esterly NB, Heskel N, et al. Eosinophilic pustular folliculitis in infancy. Pediatr Dermatol. 1984;1(3):202–6.CrossRefGoogle Scholar
  19. 19.
    Boone M, Dangoisse C, Andre J, et al. Eosinophilic pustular folliculitis in three atopic children with hypersensitivity to Dermatophagoides pteronyssinus. Dermatology. 1995;190(2):164–8.CrossRefGoogle Scholar
  20. 20.
    Hernández-Martín Á, Nuño-González A, Colmenero I, Torrelo A. Eosinophilic pustular folliculitis of infancy: a series of 15 cases and review of the literature. J Am Acad Dermatol. 2013;68(1):150–5.CrossRefGoogle Scholar
  21. 21.
    Ziemer M, Böer A. Eosinophilic pustular folliculitis in infancy: not a distinctive inflammatory disease of the skin. Am J Dermatopathol. 2005;27(5):443–55.CrossRefGoogle Scholar
  22. 22.
    Nervi SJ, Schwartz RA, Dmochowski M. Eosinophilic pustular folliculitis: a 40 year retrospect. J Am Acad Dermatol. 2006;55(2):285–9.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ishiguro N, Shishido E, Okamoto R, et al. Ofuji’s disease: a report on 20 patients with clinical and histopathologic analysis. J Am Acad Dermatol. 2002;46(6):827–33.CrossRefGoogle Scholar
  24. 24.
    Falanga V. Infantile acropustulosis with eosinophilia. J Am Acad Dermatol. 1985;13(5 Pt 1):826–8.CrossRefGoogle Scholar
  25. 25.
    Mancini AJ, Frieden IJ, Paller AS. Infantile acropustulosis revisited: history of scabies and response to topical corticosteroids. Pediatr Dermatol. 1998;15(5):337–41.CrossRefGoogle Scholar
  26. 26.
    Bundino S, Zina AM, Ubertalli S. Infantile acropustulosis. Dermatologica. 1982;165(6):615–9.CrossRefGoogle Scholar
  27. 27.
    Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol. 1991;127(9):1333–8.CrossRefGoogle Scholar
  28. 28.
    Zelickson BD, Muller SA. Generalized pustular psoriasis: a review of 63 cases. Arch Dermatol. 1991;127(9):1339–45.CrossRefGoogle Scholar
  29. 29.
    Navarini AA, Burden AD, Capon F, et al., ERASPEN Network. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792–9.Google Scholar
  30. 30.
    Christophers E, Metzler G, Röcken M. Bimodal immune activation in psoriasis. Br J Dermatol. 2014;170(1):59–65.CrossRefGoogle Scholar
  31. 31.
    Gibson LE, el-Azhari RA. Erythema elevatum diutinum. Clin Dermatol. 2000;18(3):295–9.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Wahl CE, Bouldin MB, Gibson LE. Erythema elevatum diutinum: clinical, histopathologic, and immunohistochemical characteristics of six patients. Am J Dermatopathol. 2005;27(5):397–400.CrossRefGoogle Scholar
  33. 33.
    Llamas-Velasco M, Stengel B, Pérez-González YC, Mentzel T. Late-stage erythema elevatum diutinum mimicking a fibroblastic tumor: a potential pitfall. Am J Dermatopathol. 2018;40(6):442–4.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Cardis MA, Sowash MG, Mosojane KI, et al. HIV-associated erythema elevatum diutinum: a case report and review of a clinically distinct variant. Dermatol Online J. 2018;24(5):15.Google Scholar
  35. 35.
    Creus L, Salleras M, Sola MA, et al. Erythema elevatum diutinum associated with pulmonary infiltrates. Br J Dermatol. 1997;137(4):652–3.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Ackerman AB, Chongchitnant N, Sanchez J, Guo J. Histologic diagnosis of inflammatory skin diseases: an algorithmic method based on pattern analysis. 2nd ed. Williams and Wilkins; Philadelphia. 1997. p. 488.Google Scholar
  37. 37.
    Ziemer M, Koehler MJ, Weyers W. Erythema elevatum diutinum – a chronic leukocytoclastic vasculitis microscopically indistinguishable from granuloma faciale? J Cutan Pathol. 2011;38(11):876–83.CrossRefGoogle Scholar
  38. 38.
    Dicken C, Seehafer J. Bowel bypass syndrome. Arch Dermatol. 1979;115(7):837–9.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Kemp DR, Gin D. Bowel-associated dermatosis-arthritis syndrome. Med J Aust. 1990;152:43–5.CrossRefGoogle Scholar
  40. 40.
    Ashchyan HJ, Nelson CA, Stephen S, et al. Neutrophilic dermatoses. Part II. Pyoderma gangrenosum and other bowel- and arthritis-associated neutrophilic dermatoses. J Am Acad Dermatol. 2018;79(6):1009–22.CrossRefGoogle Scholar
  41. 41.
    Marzano AV, Ishak RS, Saibeni S, et al. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a com- prehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013;45(2):202–10.CrossRefGoogle Scholar
  42. 42.
    Ely PH. The bowel bypass syndrome: a response to bacterial peptidoglycans. J Am Acad Dermatol. 1980;2(6):473–87.CrossRefGoogle Scholar
  43. 43.
    Delaney TA, Clay CD, Randell PL. The bowel-associated dermatosis—arthritis syndrome. Australas J Dermatol. 1989;30(1):23–7.CrossRefGoogle Scholar
  44. 44.
    Cugno M, Gualtierotti R, Meroni PL, Marzano AV. Inflammatory joint disorders and neutrophilic dermatoses: a comprehensive review. Clin Rev Allerg Immunol. 2018;54(2):269–81.CrossRefGoogle Scholar
  45. 45.
    Andre M, Aumaitre O, Papo T, et al. Disseminated aseptic abscesses associated with Crohn’s disease: a new entity. Dig Dis Sci. 1998;43(2):420–8.CrossRefGoogle Scholar
  46. 46.
    Kennedy C. The spectrum of inflammatory skin disease following jejuno-ileal bypass for morbid obesity. Br J Dermatol. 1981;105(4):425–35.CrossRefGoogle Scholar
  47. 47.
    Harrist TJ, Fine JD, Berman RS, et al. Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy. Arch Dermatol. 1982;118(4):263–6.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Marini M, Wright D, Ropolo M. Neutrophilic eccrine hidradenitis secondary to topotecan. J Dermatolog Treat. 2002;13(1):35–7.CrossRefGoogle Scholar
  49. 49.
    Turan H, Kaya E, Gurlevik Z, et al. Neutrophilic eccrine hidradenitis induced by cetuximab. Cutan Ocul Toxicol. 2012;31(2):148–50.CrossRefGoogle Scholar
  50. 50.
    Dib EG, Ifthikharuddin JJ, Scott GA, et al. Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy. Leuk Res. 2005;29(2):233–4.CrossRefGoogle Scholar
  51. 51.
    Herms F, Franck N, Kramkimel N, et al. Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event. Br J Dermatol. 2017;176(6):1645–8.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Bachmeyer C, Reygagne P, Aractingi S. Recurrent neutrophilic eccrine hidradenitis in an HIV-1-infected patient. Dermatology. 2000;200(4):328–30.CrossRefGoogle Scholar
  53. 53.
    Nijsten TE, Meuleman L, Lambert J. Chronic pruritic neutrophilic eccrine hidradenitis in a patient with Behçet’s disease. Br J Dermatol. 2002;147(4):797–800.CrossRefGoogle Scholar
  54. 54.
    Brehler R, Reimann S, Bonsmann G, Metze D. Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands. Am J Dermatopathol. 1997;19(1):73–8.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Bailey DL, Barron D, Lucky AW. Neutrophilic eccrine hidradenitis: a case report and review of the literature. Pediatr Dermatol. 1989;6(1):33–8.CrossRefGoogle Scholar
  56. 56.
    Stahr BJ, Cooper PH, Caputo RV. Idiopathic plantar hidradenitis: a neutrophilic eccrine hidradenitis occurring primarily in children. J Cutan Pathol. 1994;21(4):289–96.CrossRefGoogle Scholar
  57. 57.
    Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol. 1964;76:349–56.CrossRefGoogle Scholar
  58. 58.
    Rochet NM, Chavan RN, Cappel MA, et al. Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol. 2013;69(4):557–64.CrossRefGoogle Scholar
  59. 59.
    Satra K, Zalka A, Cohen PR, Grossman ME. Sweet’s syndrome and pregnancy. J Am Acad Dermatol. 1994;30(2 Pt 2):297–300.CrossRefGoogle Scholar
  60. 60.
    Amouri M, Masmoudi A, Ammar M, et al. Sweet’s syndrome: a retrospective study of 90 cases from a tertiary care center. Int J Dermatol. 2016;55(9):1033–9.CrossRefGoogle Scholar
  61. 61.
    Cohen PR, Kurzrock R. Sweet’s syndrome: a review of current treatment options. Am J Clin Dermatol. 2002;3(2):117–31.CrossRefGoogle Scholar
  62. 62.
    Marcoval J, Martín-Callizo C, Valentí-Medina F, et al. Sweet syndrome: long-term follow-up of 138 patients. Clin Exp Dermatol. 2016;41(7):741–6.CrossRefGoogle Scholar
  63. 63.
    Bidyasar S, Montoya M, Suleman K, Markowitz AB. Sweet syndrome associated with granulocyte colony-stimulating factor. J Clin Oncol. 2008;26(26):4355–6.CrossRefGoogle Scholar
  64. 64.
    Giasuddin AS, El-Orfi AH, Ziu MM, El-Barnawi NY. Sweet’s syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol. 1998;39(6):940–3.CrossRefGoogle Scholar
  65. 65.
    Imhof L, Meier B, Frei P, et al. Severe Sweet’s syndrome with elevated cutaneous interleukin-1β after azathioprine exposure: case report and review of the literature. Dermatology. 2015;230(4):293–8.CrossRefGoogle Scholar
  66. 66.
    Miyoshi T, Yamashita K, Ohno T, et al. Familial Mediterranean fever gene as a possible modifier of Sweet syndrome with chronic myelogenous leukemia. Acta Haematol. 2008;120(1):57–62.CrossRefGoogle Scholar
  67. 67.
    Torrelo A, Patel S, Colmenero I, et al. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. J Am Acad Dermatol. 2010;62(3):489–95.CrossRefGoogle Scholar
  68. 68.
    Baartman B, Kosari P, Warren CC, et al. Sight-threatening ocular manifestations of acute febrile neutrophilic dermatosis (Sweet’s syndrome). Dermatology. 2014;228(3):193–7.CrossRefGoogle Scholar
  69. 69.
    Su WP, Liu HN. Diagnostic criteria for Sweet’s syndrome. Cutis. 1986;37(3):167–74.PubMedGoogle Scholar
  70. 70.
    Magro CM, Momtahen S, Nguyen GH, Wang X. Histiocytoid Sweet’s syndrome: a localized cutaneous proliferation of macrophages frequently associated with chronic myeloproliferative disease. Eur J Dermatol. 2015;25(4):335–41.PubMedGoogle Scholar
  71. 71.
    Rahier JF, Lion L, Dewit O, Lambert M. Regression of Sweet’s syndrome associated with Crohn’s disease after anti-tumor necrosis factor therapy. Acta Gastroenterol Belg. 2005;68(3):376–9.PubMedGoogle Scholar
  72. 72.
    Cohen PR. Neutrophilic dermatoses: a review of current treatment options. Am J Clin Dermatol. 2009;10(5):301–12.CrossRefGoogle Scholar
  73. 73.
    Requena L, Kutzner H, Palmedo G, et al. Histiocytoid Sweet syndrome. A dermal infiltration of immature neutrophilic granulocytes. Arch Dermatol. 2005;141(7):834–42.CrossRefGoogle Scholar
  74. 74.
    Strutton G, Weedon D, Robertson I. Pustular vasculitis of the hands. J Am Acad Dermatol. 1995;32(2Pt1):192–8.CrossRefGoogle Scholar
  75. 75.
    Galaria NA, Junkins-Hopkins JM, Kligman D, James WD. Neutrophilic dermatosis of the dorsal hands: pustular vasculitis revisited. J Am Acad Dermatol. 2000;43(5Pt1):870–4.CrossRefGoogle Scholar
  76. 76.
    Weenig RH, Bruce AJ, McEvoy MT, et al. Neutrophilic dermatosis of the hands: for new cases and review of the literature. Int J Dermatol. 2004;43(2):95–102.CrossRefGoogle Scholar
  77. 77.
    Stransky L, Broshtilova V. Neutrophilic dermatosis of the dorsal hands elicited by thermal injury. Contact Dermatitis. 2003;49(1):42.CrossRefGoogle Scholar
  78. 78.
    Duquia RP, Almeida HL Jr, Vettorato G, et al. Neutrophilic dermatosis of the dorsal hands: acral Sweet syndrome? Int J Dermatol. 2006;45(1):51–2.CrossRefGoogle Scholar
  79. 79.
    Walling HW, Snipes CJ, Gerami P, Piette WW. The relationship between neutrophilic dermatosis of the dorsal hands and Sweet syndrome: report of 9 cases and comparison to atypical pyoderma gangrenosum. Arch Dermatol. 2006;142(1):57–63.CrossRefGoogle Scholar
  80. 80.
    Cravo M, Cardoso JC, Tellechea O, et al. Neutrophilic dermatosis of the dorsal hands associated with hypopharyngeal carcinoma. Dermatol Online J. 2008;14(7):5.PubMedGoogle Scholar
  81. 81.
    Cohen PR. Skin lesions of Sweet syndrome and its dorsal hand variant contain vasculitis: an oxymoron or an epiphenomenon? Arch Dermatol. 2002;138(3):400–3.CrossRefGoogle Scholar
  82. 82.
    Jaimes-Lopez N, Molina V, Arroyave JE, et al. Development of pyoderma gangrenosum during therapy with infliximab. J Dermatol Case Rep. 2009;3(2):20–3.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Marzano AV, Cugno M, Trevisan V, et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol. 2010;162(1):100–7.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Marzano AV, Borghi A, Meroni PL, Cugno M. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016;175(5):882–91.CrossRefGoogle Scholar
  85. 85.
    Powell FC, Su WPD, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34(3):395–409.CrossRefGoogle Scholar
  86. 86.
    Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine. 2009;88(1):23–31.CrossRefGoogle Scholar
  87. 87.
    Broekaert SM, Böer-Auer A, Kerl K, et al. Neutrophilic epitheliotropism is a histopathological clue to neutrophilic urticarial dermatosis. Am J Dermatopathol. 2016;38(1):39–49.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Willis WF. The gyrate erythemas. Int J Dermatol. 1978;17(9):698–702.CrossRefGoogle Scholar
  90. 90.
    Rasmussen ER, de Freitas PV, Bygum A. Urticaria and prodromal symptoms including erythema marginatum in danish patients with hereditary angioedema. Acta Derm Venereol. 2016;96(3):373–6.CrossRefGoogle Scholar
  91. 91.
    Farkas H, Harmat G, Fáy A, et al. Erythema marginatum preceding an acute oedematous attack of hereditary angioneurotic oedema. Acta Derm Venereol. 2001;81(5):376–7.CrossRefGoogle Scholar
  92. 92.
    Stollerman GH. Changing streptococci and prospects for the global eradication of rheumatic fever. Perspect Biol Med. 1997;40(2):165–89.CrossRefGoogle Scholar
  93. 93.
    Soria C, Allegue F, España A, et al. Vegetating iododerma with underlying systemic diseases: report of three cases. J Am Acad Dermatol. 1990;22(3):418–42.CrossRefGoogle Scholar
  94. 94.
    Sterling JB, Heymann WR. Potassium iodide in dermatology: a 19th century drug for the 21st century – uses, pharmacology, adverse effects, and contraindications. J Am Acad Dermatol. 2000;43(4):691–7.CrossRefGoogle Scholar
  95. 95.
    Wells GC, Smith N. Eosinophilic cellulitis. Br J Dermatol. 1979;199(1):101–9.CrossRefGoogle Scholar
  96. 96.
    Ackerman AB. Eosinophilic cellulitis (Wells’ Syndrome)? From: Accessed 25 Nov 2018.
  97. 97.
    Melski JW. Wells’ syndrome, insect bites, and eosinophils. Dermatol Clin. 1990;8(2):287–93.CrossRefGoogle Scholar
  98. 98.
    Schorr WF, Tauscheck AL, Dickson KB, Melski JW. Eosinophilic cellulitis (Wells’ syndrome): histologic and clinical features in arthropod bite reactions. J Am Acad Dermatol. 1984;11(6):1043–9.CrossRefGoogle Scholar
  99. 99.
    Weedon D. Skin pathology. 3rd ed. Churchill-Livingstone Elsevier; London. 2010. p. 940–41.Google Scholar
  100. 100.
    Spigel GT, Winkelmann RK. Wells’ syndrome: recurrent granulomatous dermatitis with eosinophilia. Arch Dermatol. 1979;115(5):611–3.CrossRefGoogle Scholar
  101. 101.
    Prakash Babu S, Chen YK, Bonne-Annee S, et al. Dysregulation of interleukin 5 expression in familial eosinophilia. Allergy. 2017;72(9):1338–45.CrossRefGoogle Scholar
  102. 102.
    Dispenza MC, Bochner BS. Diagnosis and novel approaches to the treatment of hypereosinophilic syndromes. Curr Hematol Malig Rep. 2018;13(3):191–201.CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92(11):1243–59.CrossRefGoogle Scholar
  104. 104.
    Fitzpatrick JE, Johnson C, Simon P, et al. Cutaneous microthrombi: a histologic clue to the diagnosis of hypereosinophilic syndrome. Am J Dermatopathol. 1987;9(5):419–22.CrossRefGoogle Scholar
  105. 105.
    Rueda RA, Valencia IC, Covelli C, et al. Eosinophilic, polymorphic, and pruritic eruption associated with radiotherapy. Arch Dermatol. 1999;135(7):804–10.CrossRefGoogle Scholar
  106. 106.
    van Kester MS, Quint KD. Eosinophilic, polymorphic, and pruritic eruption associated with radiotherapy on the skin of the right breast. JAMA Oncol. 2016;2(5):677–8.CrossRefGoogle Scholar
  107. 107.
    Gallego H, Crutchfield CE 3rd, Wilke MS, Lewis EJ. Delayed EPPER syndrome. Arch Dermatol. 2001;137(6):821–2.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Unit of Dermatopathology, Department of DermatologyTechnical University of Munich, School of MedicineMunichGermany
  2. 2.Department of DermatologyUniversity Hospital MünsterMünsterGermany

Personalised recommendations